Akebia Therapeutics (AKBA) Operating Expenses: 2016-2025
Historic Operating Expenses for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $44.9 million.
- Akebia Therapeutics' Operating Expenses rose 25.61% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.0 million, marking a year-over-year increase of 11.76%. This contributed to the annual value of $147.5 million for FY2024, which is 11.55% down from last year.
- Akebia Therapeutics' Operating Expenses amounted to $44.9 million in Q3 2025, which was up 16.82% from $38.5 million recorded in Q2 2025.
- Akebia Therapeutics' 5-year Operating Expenses high stood at $88.8 million for Q1 2022, and its period low was $35.3 million during Q2 2024.
- Its 3-year average for Operating Expenses is $39.4 million, with a median of $37.1 million in 2023.
- In the last 5 years, Akebia Therapeutics' Operating Expenses slumped by 48.89% in 2023 and then grew by 25.61% in 2025.
- Quarterly analysis of 5 years shows Akebia Therapeutics' Operating Expenses stood at $75.4 million in 2021, then declined by 15.00% to $64.1 million in 2022, then crashed by 43.58% to $36.2 million in 2023, then grew by 11.84% to $40.4 million in 2024, then climbed by 25.61% to $44.9 million in 2025.
- Its Operating Expenses was $44.9 million in Q3 2025, compared to $38.5 million in Q2 2025 and $36.2 million in Q1 2025.